申请人:Gagnon Lyne
公开号:US20130225683A1
公开(公告)日:2013-08-29
New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I, IA, IB and IC, and their pharmaceutical acceptable salts are described for prevention or treatment of diabetes or a diabetes-related disorder in a subject in need thereof. Diabetes and diabetes-related disorder include Type I diabetes, Type II diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes of adults (LADA), gestational diabetes, diabetic nephropathy, proteinuria, ketonuria, obesity, hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia, hypercholesterolemia, hypertension, hyperlipoproteinemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, metabolic syndrome, syndrome X, diabetic neuropathy, diabetic retinopathy, hypoglycemia, cardiovascular disease, atherosclerosis, diabetic kidney disease, ketoacidosis, thrombotic disorders, sexual dysfunction, dermatopathy, edema, metabolic syndrome and renal disorders. The related pharmaceutical compositions and methods are also described. These compounds can be used in combination with comprising a therapeutic agent for lowering or controlling blood glucose level such as metformin or a thiazolidinedione.
本文描述了苯丙酮羧酸酯化合物和公式I、公式I、IA、IB和IC的取代芳香族化合物及其药物可接受的盐的新用途,用于预防或治疗需要的患有糖尿病或糖尿病相关疾病的受试者。糖尿病和糖尿病相关疾病包括1型糖尿病、2型糖尿病、成年发病型糖尿病、成人隐性自身免疫性糖尿病(LADA)、妊娠期糖尿病、糖尿病肾病、蛋白尿、酮尿症、肥胖症、高血糖、葡萄糖耐受不良、胰岛素抵抗、高胰岛素血症、高胆固醇血症、高血压、高脂蛋白血症、高脂血症、高三酸甘油酯血症、代谢综合征、X综合征、糖尿病神经病变、糖尿病视网膜病变、低血糖、心血管疾病、动脉硬化、糖尿病肾病、酮症酸中毒、血栓性疾病、性功能障碍、皮肤病、水肿、代谢综合征和肾脏疾病。同时还描述了相关的药物组合和方法。这些化合物可以与降低或控制血糖水平的治疗剂如二甲双胍或噻唑烷二酮一起使用。